Isolation and quantification of N-glycans from immunoglobulin G antibodies for quantitative glycosylation analysis
Main Article Content
Keywords
2-aminobenzamide (2-AB), HILIC-HPLC, monoclonal antibody (mAb), N-glycans, PNGase F, protein-A
Abstract
N-glycosylation is one of the critical quality attributes for the therapeutic monoclonal antibodies. Characterization of N-glycans of monoclonal antibodies provides valuable information about its therapeutic efficacy. We present a non-invasive method of isolating N-glycans from Immunoglobulin G based antibodies for glycosylation analysis. The method consists of purification of antibodies from biological solution and release of N-glycans with peptide-N-glycosidase F in a single consolidated process using a mini affinity ligand column (e.g. protein-A column). The method is highly reproducible with average coefficient of variation of 0.012 in the glycoform percentage distributions between the replicates. The method provides quantification of the molar yield of glycans as a function of molar concentration of antibody in a single analysis. To our knowledge, this is the first time this approach was used to detect and quantify any macro-heterogeneity of N-glycosylation in monoclonal antibody samples. This fairly rapid and very cost-efficient method would be of great interest for academic labs and biopharmaceutical industries.
Downloads
Metrics
References
2. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, et al. (2002) Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 277: 26733-26740.
3. Hodoniczky J, Zheng YZ, James DC (2005) Control of Recombinant Monoclonal Antibody Effector Functions by Fc N-Glycan Remodeling in Vitro. Biotechnol Prog 21: 1644-1652.
4. Boyd PN, Lines AC, Patel AK (1995) The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Molecular Immunology 32: 1311-1318.
5. Houde D, Peng Y, Berkowitz SA, Engen JR (2010) Post-translational Modifications Differentially Affect IgG1 Conformation and Receptor Binding. Molecular & Cellular Proteomics 9: 1716-1728.
6. Kumpel BM, Wang Y, Griffiths HL, Hadley AG, Rook GAW (1995) The biological activity of human monoclonal IgG anti-D is reduced by beta-galactosidase treatment. Human Antibodies and Hybridomas 6: 82-88.
7. Scallon BJ, Tam SH, McCarthy SG, Cai AN, Raju TS (2007) Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Molecular Immunology 44: 1524-1534.
8. Kaneko Y, Nimmerjahn F, Ravetch JV (2006) Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313: 670-673.
9. Ghaderi D, Taylor RE, Padler-Karavani V, Diaz S, Varki A (2010) Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nat Biotech 28: 863-867.
10. Chung CH, Mirakhur B, Chan E, Le Q-T, Berlin J, et al. (2008) Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose. New England Journal of Medicine 358: 1109-1117.
11. Zheng K, Bantog C, Bayer R (2011) The impact of glycosylation on monoclonal antibody conformation and stability. mAbs 3: 568-576.
12. Ha S, Ou Y, Vlasak J, Li Y, Wang S, et al. (2011) Isolation and characterization of IgG1 with asymmetrical Fc glycosylation. Glycobiology 21: 1087-1096.
13. Hossler P, Khattak SF, Li ZJ (2009) Optimal and consistent protein glycosylation in mammalian cell culture. Glycobiology 19: 936-949.
14. Liu B, Spearman M, Doering J, Lattova E, Perreault H, et al. (2014) The availability of glucose to CHO cells affects the intracellular lipid-linked oligosaccharide distribution, site occupancy and the N-glycosylation profile of a monoclonal antibody. J Biotechnol 170: 17-27.
15. Moellering BJ, Tedesco JL, Townsend RR, Hardy MR, Scott RW, et al. (1989) Electrophoretic differences in a mAb expressed in three media. BioPharm International 3: 30-38.
16. Huffman JE, Pucic-Bakovic M, Klaric L, Hennig R, Selman MHJ, et al. (2014) Comparative Performance of Four Methods for High-throughput Glycosylation Analysis of Immunoglobulin G in Genetic and Epidemiological Research. Molecular & Cellular Proteomics 13: 1598-1610.
17. Mann AC, Self CH, Turner GA (1994) A general method for the complete deglycosylation of a wide variety of serum glycoproteins using peptide-N-glycosidase-F. Glycosylation & Disease 1: 253-261.
18. Melmer M, Stangler T, Schiefermeier M, Brunner W, Toll H, et al. (2010) HILIC analysis of fluorescence-labeled N-glycans from recombinant biopharmaceuticals. Anal Bioanal Chem 398: 905-914.
19. Royle L, Radcliffe CM, Dwek RA, Rudd PM (2006) Detailed structural analysis of N-glycans released from glycoproteins in SDS-PAGE gel bands using HPLC combined with exoglycosidase array digestions. Methods Mol Biol 347: 125-143.
20. Krenkova J, Lacher NA, Svec F (2009) Multidimensional system enabling deglycosylation of proteins using a capillary reactor with peptide-N-glycosidase F immobilized on a porous polymer monolith and hydrophilic interaction liquid chromatography–mass spectrometry of glycans. Journal of Chromatography A 1216: 3252-3259.
21. Bynum MA, Yin H, Felts K, Lee YM, Monell CR, et al. (2009) Characterization of IgG N-Glycans Employing a Microfluidic Chip that Integrates Glycan Cleavage, Sample Purification, LC Separation, and MS Detection. Analytical Chemistry 81: 8818-8825.
22. Royle L, Campbell MP, Radcliffe CM, White DM, Harvey DJ, et al. (2008) HPLC-based analysis of serum N-glycans on a 96-well plate platform with dedicated database software. Anal Biochem 376: 1-12.
23. Doherty M, Bones J, McLoughlin N, Telford JE, Harmon B, et al. (2013) An automated robotic platform for rapid profiling oligosaccharide analysis of monoclonal antibodies directly from cell culture. Anal Biochem 442: 10-18.
24. Bell A, Wang ZJ, Arbabi-Ghahroudi M, Chang TA, Durocher Y, et al. Differential tumor-targeting abilities of three single-domain antibody formats. Cancer Letters 289: 81-90.
25. Gonzalez TN, Leong SR, Presta LG (2000) Humanized anti-IL-8 monoclonal antibodies. USPTO: 6133426, Genentech, Inc., U.S.A.
Article Sidebar
Article Details
Authors who publish with JBM agree to the following terms:
- Authors retain copyright and grant JBM right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
